CUFinder

James D Griffin

James D Griffin

Harvard University

H-index: 139

North America-United States

Contact James D Griffin

About James D Griffin

James D Griffin, With an exceptional h-index of 139 and a recent h-index of 43 (since 2020), a distinguished researcher at Harvard University, specializes in the field of medicine, leukemia.

His recent articles reflect a diverse array of research interests and contributions to the field:

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity (vol 16, pg 483, 2010)

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

James D Griffin Information

University

Position

Dana-Farber Cancer Institute

Citations(all)

72592

Citations(since 2020)

9456

Cited By

65699

hIndex(all)

139

hIndex(since 2020)

43

i10Index(all)

431

i10Index(since 2020)

188

Email

University Profile Page

Google Scholar

James D Griffin Skills & Research Interests

medicine

leukemia

Top articles of James D Griffin

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Iscience

2024/4/19

Peter Keane
Peter Keane

H-Index: 6

Sophie Kellaway
Sophie Kellaway

H-Index: 2

Helen Blair
Helen Blair

H-Index: 15

Naeem Khan
Naeem Khan

H-Index: 1

James Griffin
James Griffin

H-Index: 5

John Bushweller
John Bushweller

H-Index: 26

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity (vol 16, pg 483, 2010)

Nature medicine

2010/4

Nicholas Mitsiades
Nicholas Mitsiades

H-Index: 41

James D Griffin
James D Griffin

H-Index: 47

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Nature medicine

2024/2/14

Nicholas Mitsiades
Nicholas Mitsiades

H-Index: 41

James D Griffin
James D Griffin

H-Index: 47

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

Haematologica

2023

Fen Zhu
Fen Zhu

H-Index: 7

Wei Ni
Wei Ni

H-Index: 5

Swati Garg
Swati Garg

H-Index: 3

Lixin Rui
Lixin Rui

H-Index: 15

James Griffin
James Griffin

H-Index: 5

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Patient preference and adherence

2023/12/31

James D Griffin
James D Griffin

H-Index: 47

Mo Zhou
Mo Zhou

H-Index: 2

Hongbo Yang
Hongbo Yang

H-Index: 14

Yan Song
Yan Song

H-Index: 9

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

Cell Reports

2023/12/26

Peter Keane
Peter Keane

H-Index: 6

Helen Blair
Helen Blair

H-Index: 15

James Griffin
James Griffin

H-Index: 5

John Bushweller
John Bushweller

H-Index: 26

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations

2023/11/12

Swati Garg
Swati Garg

H-Index: 3

Wei Ni
Wei Ni

H-Index: 5

James D Griffin
James D Griffin

H-Index: 47

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

New England journal of medicine

2023/7/27

Binod Dhakal
Binod Dhakal

H-Index: 2

Kwee Yong
Kwee Yong

H-Index: 27

Andrew Spencer
Andrew Spencer

H-Index: 23

Seok Jin Kim
Seok Jin Kim

H-Index: 33

James Griffin
James Griffin

H-Index: 5

Jane Gilbert
Jane Gilbert

H-Index: 7

Sarah Nagle
Sarah Nagle

H-Index: 1

Nitin Patel
Nitin Patel

H-Index: 4

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

2023/6

James D Griffin
James D Griffin

H-Index: 47

Qingsong Liu
Qingsong Liu

H-Index: 2

Jing Yang
Jing Yang

H-Index: 14

Inhibiting β-catenin in AML by targeting DDX5

Cancer Research

2023/4/4

Wei Ni
Wei Ni

H-Index: 5

Swati Garg
Swati Garg

H-Index: 3

Fen Zhu
Fen Zhu

H-Index: 7

Basudev Chowdhury
Basudev Chowdhury

H-Index: 9

Lizi Wu
Lizi Wu

H-Index: 26

James D Griffin
James D Griffin

H-Index: 47

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: repurposing clinically available drugs for COVID‐19 therapy

Journal of medical virology

2023/1

Jinhua Wang
Jinhua Wang

H-Index: 31

James D Griffin
James D Griffin

H-Index: 47

Suryaram Gummuluru
Suryaram Gummuluru

H-Index: 22

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

Leukemia

2022/4

Jing Yang
Jing Yang

H-Index: 14

Wei Ni
Wei Ni

H-Index: 5

Zuowei Wang
Zuowei Wang

H-Index: 17

Tao Huang
Tao Huang

H-Index: 2

Jing Liu
Jing Liu

H-Index: 11

Qingsong Liu
Qingsong Liu

H-Index: 2

James D Griffin
James D Griffin

H-Index: 47

Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2

Leukemia

2022/1

Jing Yang
Jing Yang

H-Index: 14

Xiaoxi Liu
Xiaoxi Liu

H-Index: 20

Wai Cheung Chan
Wai Cheung Chan

H-Index: 2

Bin Hu
Bin Hu

H-Index: 11

Richard Stone
Richard Stone

H-Index: 27

James D Griffin
James D Griffin

H-Index: 47

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Blood cancer journal

2022/7/19

Basudev Chowdhury
Basudev Chowdhury

H-Index: 9

Wei Ni
Wei Ni

H-Index: 5

Swati Garg
Swati Garg

H-Index: 3

Abdel Kareem Azab
Abdel Kareem Azab

H-Index: 29

Jennifer Sun
Jennifer Sun

H-Index: 5

Barbara Muz
Barbara Muz

H-Index: 17

Dana Sanchez
Dana Sanchez

H-Index: 7

Xin Chen
Xin Chen

H-Index: 14

William Forrester
William Forrester

H-Index: 7

James D Griffin
James D Griffin

H-Index: 47

P395: PHARMACEUTICAL TARGETING OF RAS IN ACUTE MYELOID LEUKAEMIA

HemaSphere

2022/6/1

Daniel Coleman
Daniel Coleman

H-Index: 14

James Griffin
James Griffin

H-Index: 5

Peter Cockerill
Peter Cockerill

H-Index: 22

Maintenance Therapy in Patients with FLT3-ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Blood

2021/11/23

Hongbo Yang
Hongbo Yang

H-Index: 14

Yan Song
Yan Song

H-Index: 9

James D Griffin
James D Griffin

H-Index: 47

Patient and physician preferences for treatment of newly diagnosed acute myeloid leukemia (AML) in patients not candidates for intensive chemotherapy

Blood

2021/11/23

Mo Zhou
Mo Zhou

H-Index: 2

Hongbo Yang
Hongbo Yang

H-Index: 14

Yan Song
Yan Song

H-Index: 9

James D Griffin
James D Griffin

H-Index: 47

Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes

European Journal of Haematology

2021/11

James D Griffin
James D Griffin

H-Index: 47

Yan Song
Yan Song

H-Index: 9

Hongbo Yang
Hongbo Yang

H-Index: 14

Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators

2021/2/23

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

Leukemia & Lymphoma

2021/5/14

Kinan Alhallak
Kinan Alhallak

H-Index: 7

Amanda Jeske
Amanda Jeske

H-Index: 1

Jennifer Sun
Jennifer Sun

H-Index: 5

Barbara Muz
Barbara Muz

H-Index: 17

Ilyas Sahin
Ilyas Sahin

H-Index: 13

James D Griffin
James D Griffin

H-Index: 47

Abdel Kareem Azab
Abdel Kareem Azab

H-Index: 29

See List of Professors in James D Griffin University(Harvard University)